STRO SUTRO BIOPHARMA INC revenue, earnings and financials

For the quarter ended June 30, 2026, SUTRO BIOPHARMA INC reported revenue of $9.84M (down 84.6% from a year earlier), net income of −$38.5M and diluted EPS of −$2.33; over the last four quarters revenue was $45.7M and net income −$181M; for the fiscal year ended December 2025 revenue was $102M, up 65.2% on the year before.

STRO annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $102M, gross profit n/a, operating income −$158M, net income −$191M (margin -186.4%), EPS −$22.49
• Fiscal year ended Dec 2024: revenue $62.0M, gross profit n/a, operating income −$238M, net income −$227M (margin -365.9%), EPS −$29.40
• Fiscal year ended Dec 2023: revenue $154M, gross profit n/a, operating income −$89.3M, net income −$107M (margin -69.6%), EPS −$1.78
• Fiscal year ended Dec 2022: revenue $67.8M, gross profit n/a, operating income −$129M, net income −$119M (margin -175.9%), EPS −$2.35
• Fiscal year ended Dec 2021: revenue $61.9M, gross profit n/a, operating income −$98.5M, net income −$106M (margin -170.6%), EPS −$2.29

STRO quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $9.84M (down 84.6% year over year), net income −$38.5M, EPS −$2.33
• Quarter ended Mar 31, 2026: revenue $14.5M (down 16.5% year over year), net income −$38.5M, EPS −$2.94
• Quarter ended Dec 31, 2025 (from the annual report): revenue $11.6M (down 21.4% year over year), net income −$46.7M, EPS −$11.39
• Quarter ended Sep 30, 2025: revenue $9.69M (up 13.8% year over year), net income −$56.9M, EPS −$0.67
• Quarter ended Jun 30, 2025: revenue $63.7M (up 148.0% year over year), net income −$11.5M, EPS −$1.35
• Quarter ended Mar 31, 2025: revenue $17.4M (up 33.8% year over year), net income −$76.0M, EPS −$9.08
• Quarter ended Dec 31, 2024 (from the annual report): revenue $14.8M (down 87.0% year over year), net income −$72.0M, EPS −$27.63
• Quarter ended Sep 30, 2024: revenue $8.52M (down 49.7% year over year), net income −$48.8M, EPS −$0.59
• Quarter ended Jun 30, 2024: revenue $25.7M (up 146.9% year over year), net income −$48.0M, EPS −$0.59
• Quarter ended Mar 31, 2024: revenue $13.0M (up 2.6% year over year), net income −$58.2M, EPS −$0.59
• Quarter ended Dec 31, 2023 (from the annual report): revenue $114M (up 1217.4% year over year), net income $30.9M, EPS $0.52
• Quarter ended Sep 30, 2023: revenue $16.9M (down 32.7% year over year), net income −$49.3M, EPS −$0.81
• Quarter ended Jun 30, 2023: revenue $10.4M (down 62.9% year over year), net income −$38.5M, EPS −$0.64
• Quarter ended Mar 31, 2023: revenue $12.7M (up 114.9% year over year), net income −$50.1M, EPS −$0.85
• Quarter ended Dec 31, 2022 (from the annual report): revenue $8.63M (down 19.0% year over year), net income −$34.6M, EPS −$0.59
• Quarter ended Sep 30, 2022: revenue $25.1M (up 195.3% year over year), net income −$19.5M, EPS −$0.37
• Quarter ended Jun 30, 2022: revenue $28.1M (up 0.2% year over year), net income −$26.0M, EPS −$0.55
• Quarter ended Mar 31, 2022: revenue $5.90M (down 59.8% year over year), net income −$39.1M, EPS −$0.84
• Quarter ended Dec 31, 2021 (from the annual report): revenue $10.7M, net income −$38.1M, EPS −$0.83
• Quarter ended Sep 30, 2021: revenue $8.52M, net income −$30.9M, EPS −$0.67

STRO cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$177M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$192M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$112M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow $3.55M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$81.7M, share buybacks $7.00K

STRO balance sheet

• Jun 30, 2026: cash $54.3M, total assets $194M, total liabilities $298M, shareholders' equity −$103M
• Mar 31, 2026: cash $73.7M, total assets $242M, total liabilities $309M, shareholders' equity −$66.9M
• Dec 31, 2025: cash $58.1M, total assets $174M, total liabilities $306M, shareholders' equity −$132M
• Sep 30, 2025: cash $65.9M, total assets $210M, total liabilities $297M, shareholders' equity −$87.3M
• Jun 30, 2025: cash $64.0M, total assets $262M, total liabilities $294M, shareholders' equity −$32.1M
• Mar 31, 2025: cash $106M, total assets $321M, total liabilities $347M, shareholders' equity −$25.8M
• Dec 31, 2024: cash $190M, total assets $387M, total liabilities $343M, shareholders' equity $44.6M
• Sep 30, 2024: cash $175M, total assets $452M, total liabilities $341M, shareholders' equity $111M

What is STRO's revenue?

SUTRO BIOPHARMA INC reported $45.7M of revenue over its last four quarters, through June 30, 2026.

Is STRO profitable?

No. SUTRO BIOPHARMA INC lost $181M over the last four quarters.

What is STRO's EPS?

Diluted earnings per share over the last four quarters were −$17.33; −$2.33 in the latest quarter.

STRO ownership and insider trades · All stocks